Suchen
Sophia Genetics SA
SOPHZur Watchlist hinzufügen
5.350USD
-0.240-4.29%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
384.08MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Sophia Genetics SA Unternehmen
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics SA Informationen
BörsenkürzelSOPH
Name des UnternehmensSOPHiA GENETICS SA
IPO-datumJul 23, 2021
CEOCamblong (Jurgi)
Anzahl der mitarbeiter423
WertpapierartOrdinary Share
GeschäftsjahresendeJul 23
AddresseLa Piece 12
StadtROLLE
BörseNASDAQ OMX - NASDAQ BASIC
LandSwitzerland
PostleitzahlCH-1180
Telefon41216941060
Websitehttps://www.sophiagenetics.com/
BörsenkürzelSOPH
IPO-datumJul 23, 2021
CEOCamblong (Jurgi)
Führungskräfte von Sophia Genetics SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.98M
-0.94%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
625.61K
-0.07%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
509.18K
-0.79%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
489.08K
+4.03%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
294.96K
+6.69%
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
217.28K
+8.85%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
204.44K
+9.65%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
128.68K
-7.77%
Mr. Daan Van Well
Mr. Daan Van Well
Chief Legal and Compliance Officer
Chief Legal and Compliance Officer
--
--
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.98M
-0.94%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
625.61K
-0.07%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
509.18K
-0.79%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
489.08K
+4.03%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
294.96K
+6.69%
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
217.28K
+8.85%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Sophia Genetics SA?
Die fünf größten Anteilseigner von Sophia Genetics SA sind: Dr. Jurgi Camblong, Ph.D.
Wie viele Institutionen halten Anteile an Sophia Genetics SA (SOPH)?
Mit Stand vom 2026Q1 halten 89 Institutionen Anteile an Sophia Genetics SA, mit einem Gesamtmarktwert von etwa 27.73M, was 38.63% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -11894064.00 gestiegen.